In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Erytech Pharma SA (ERYP – Research Report). The company’s shares closed last Monday at $3.34.
According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of -7.8% and a 36.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Hold analyst consensus rating for Erytech Pharma SA.
See the top stocks recommended by analysts >>
The company has a one-year high of $13.00 and a one-year low of $4.10. Currently, Erytech Pharma SA has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
Read More on ERYP:
